CLARITY PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Copper-67 SAR-bisPSMA updates 2024-10-16 21:03
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort 2024-09-12 21:03
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range 2024-03-08 22:02
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level 2023-11-30 21:59
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial 2023-08-25 20:58
Clarity's theranostic prostate cancer trial advances to cohort 2 2023-05-24 21:03
Fifty percent recruitment milestone for PROPELLER prostate cancer trial 2021-12-01 21:57
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed 2021-11-10 22:06
1